Corcept Therapeutics price target lowered to $135 from $150 at Truist

TipRanks

Wed, May 7, 2025, 7:01 AM 1 min read

Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with the pharmacy vendor, the analyst tells investors in a research note. More concerning is if demand for relacorilant, which is modeled to be a larger product, would be met if approved by December 30 PDUFA, the firm adds.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CORT:

Disclaimer & DisclosureReport an Issue

• Corcept Therapeutics: Strong Growth Potential and Promising Pipeline Support Buy Rating

• Corcept Therapeutics price target lowered to $145 from $150 at H.C. Wainwright

• Corcept Therapeutics Reports Q1 2025 Financial Results

• Closing Bell Movers: Palantir falls 9%, Ford down 2% on earnings

• Corcept Therapeutics reports Q1 EPS 17c, consensus 14c